| Literature DB >> 34882365 |
Walter J Gomes1,2, Isadora Rocco1,2, Wallace S Pimentel1, Aislan H B Pinheiro1, Paulo M S Souza1, Luiz A A Costa1, Marjory M P Teixeira1, Leonardo P Ohashi1, Caroline Bublitz1, Isis Begot1, Rita Simone L Moreira3, Nelson A Hossne1, Guilherme F Vargas1, João Nelson R Branco1, Carlos A Teles1, Eduardo A S Medeiros1, Camila Sáfadi4, Amândio Rampinelli5, Leopoldo Moratelli5, Anderson Rosa Rosado5, Franciele Kuhn Mesacasa5, Ismael Escobar Capriata5, Rodrigo Coelho Segalote6, Deborah Louize da Rocha Vianna Palmieri6, Amanda Cristina Mendes Jardim6, Diego Sarty Vianna6, Joaquim Henrique de Souza Aguiar Coutinho7, João Carlos Jazbik7, Henrique Madureira da Rocha Coutinho7, Gustavo Kikuta7, Zely Sant'Anna Marotti de Almeida7, Gibran Roder Feguri8, Paulo Ruiz Lucio de Lima8, Anna Carolina Franco8, Danilo de Cerqueira Borges8, Felipe Ramos Honorato De La Cruz8, Ulisses Alexandre Croti9, Bruna Cury Borim9, Carlos Henrique De Marchi9, Lilian Goraieb9, Karolyne Barroca Sanches Postigo9, Fabiano Gonçalves Jucá10, Fátima Rosane de Almeida Oliveira10, Rafael Bezerra de Souza10, Alexandre Cabral Zilli11, Raul Gaston Sanchez Mas11, Luiz Carlos Bettiati11, Ricardo Tranchesi11, Ayrton Bertini12, Leandro Vieira Franco12, Priscila Fernandes12, Fabiana Oliveira12, Roberto Moraes12, Thiago Cavalcanti Vila Nova de Araújo13, Otávio Penna Braga13, Antônio Cavalcanti Pedrosa13, Roberta Tavares Barreto Teixeira13, Irla Lavor Lucena Camboim13, Eduardo Nascimento Gomes14, Pedro Horigushi Reis14, Luara Piovan Garcia14, Nelson Henrique Goes Scorsioni14, Roberto Lago14, Solange Guizilini1,2.
Abstract
INTRODUCTION: We investigated the clinical course and outcomes of patients submitted to cardiovascular surgery in Brazil and who had developed symptoms/signs of coronavirus disease 2019 (COVID-19) in the perioperative period.Entities:
Keywords: COVID-19; Cardiac Surgical Procedures; Comorbidity; SARS-CoV-2; Thoracic Surgery
Mesh:
Year: 2021 PMID: 34882365 PMCID: PMC8641779 DOI: 10.21470/1678-9741-2021-0960
Source DB: PubMed Journal: Braz J Cardiovasc Surg ISSN: 0102-7638
Fig. 1Flowchart of patients in the study. RT-PCR=reverse transcriptase-polymerase chain reaction; SARS-CoV-2=severe acute respiratory syndrome coronavirus 2.
Patients' demographic and clinical characteristics.
| TOTAL (N=104) | ||||||
|---|---|---|---|---|---|---|
| % | Mean | ± | SD | Median | IQR | |
| Age (years) | 60.7 | ± | 12.8 | 62 | (54.5-70.0) | |
| Sex (male) | 63.7 | |||||
| Height (cm) | 166 | ± | 9.10 | 166 | (160-170) | |
| Weight (kg) | 76.0 | ± | 18.2 | 74.5 | (62.2-84.3) | |
| BMI (kg/m2) | 27.5 | ± | 5.48 | 26.5 | (23.5-31.2) | |
| Blood type | ||||||
| A | 42.9 | |||||
| B | 1.4 | |||||
| AB | 17.1 | |||||
| O | 38.6 | |||||
| Rh factor | ||||||
| Positive | 12.7 | |||||
| Negative | 87.3 | |||||
| HBP | 75.0 | |||||
| Diabetes | 40.0 | |||||
| Active smoking | 44.8 | |||||
| CAD | 66.3 | |||||
| Stroke | 5.2 | |||||
| CKD | 12.2 | |||||
| COPD | 11.2 | |||||
| Previous MI | 18.0 | |||||
| EuroSCORE II | 3.91 | ± | 3.53 | 2.46 | (1.28-5.35) | |
| Surgery timing | ||||||
| Elective | 70.1 | |||||
| Urgency | 26.2 | |||||
| Emergency | 3.7 | |||||
| Operation time (min) | 239 | ± | 87.7 | 238 | (201-295) | |
| Pump time (min) | 87.5 | 82.3 | ± | 46.1 | 83 | (56-100) |
| Mean aortic clamping time (min) | 87.5 | 67.7 | ± | 38.4 | 68 | (47-85.3) |
| Δ COVID-19/surgery time | -15.2 | ± | 47.3 | 0 | (-33.5-9.0) | |
| COVID-19 symptoms/signs | ||||||
| Dry cough | 23.2 | |||||
| Fever | 25.5 | |||||
| Fatigue | 29.8 | |||||
| Dyspnea | 43.2 | |||||
| Desaturation | 44.2 | |||||
| Headache | 4.2 | |||||
| Diarrhea | 3.2 | |||||
BMI=body mass index; CAD=coronary artery disease; CKD=chronic kidney disease; COPD=chronic obstructive pulmonary disease; COVID-19=coronavirus disease 2019; EuroSCORE II=European System for Cardiac Operative Risk Evaluation; HBP=high blood pressure (hypertension); IQR=interquartile range; MI=myocardial infarction; SD=standard deviation
Patients' characteristics according to group allocation.
| Group 1 (N=45) | Group 2 (n=37) | Group 3 (N=22) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| % | Mean ± SD | Median | IQR | % | Mean ± SD | Median | IQR | % | Mean±SD | Median | IQR | ||
| Age (years) | 57.5±13.6 | 59.0 | 48 - 66 | 63.2±10.8 | 64.5 | 55.3 - 70.0 | 63.3 ± 13.9 | 63.5 | 58 - 74 | 0.075 | |||
| Sex (male) | 64.4 | 73.7 | 50.0 | 0.193 | |||||||||
| Height (cm) | 167±8.66 | 166 | 162 - 170 | 165±6.88 | 168 | 160 - 170 | 167 ± 12.7 | 168 | 161 - 172 | 0.779 | |||
| Weight (kg) | 76.9±16.2 | 76.5 | 65 - 90 | 73.6±18.4 | 70.0 | 60.8 - 80.0 | 78.4 ± 15.8 | 75.0 | 70 -80 | 0.631 | |||
| BMI (kg/m2) | 26.9±5.75 | 26.4 | 22 - 30 | 27.2±4.99 | 25.1 | 23.4 - 31.2 | 29.2 ± 5.2 | 29.7 | 26 - 31 | 0.511 | |||
| Blood type | 0.891 | ||||||||||||
| A | 43.8 | 50.0 | 31.3 | ||||||||||
| B | 3.1 | 0.0 | 0.0 | ||||||||||
| AB | 15.6 | 18.2 | 18.8 | ||||||||||
| O | 37.5 | 31.8 | 50.0 | ||||||||||
| Rh factor | 0.416 | ||||||||||||
| Positive | 9.4 | 21.7 | 6.3 | ||||||||||
| Negative | 90.6 | 78.3 | 93.8 | ||||||||||
| HBP | 64.4 | 86.1 | 86.4 | 0.043 | |||||||||
| Diabetes | 37.8 | 38.9 | 40.9 | 0.970 | |||||||||
| Active smoking | 44.2 | 47.1 | 54.5 | 0.733 | |||||||||
| CAD | 59.1 | 68.4 | 81.8 | 0.201 | |||||||||
| Stroke | 7.0 | 5.7 | 0 | 0.717 | |||||||||
| CKD | 9.1 | 20.0 | 4.5 | 0.191 | |||||||||
| COPD | 9.1 | 14.3 | 13.6 | 0.727 | |||||||||
| Previous MI | 60.5 | 40.5 | 59.1 | 0.170 | |||||||||
| EuroSCORE II | 2.89±2.80 | 1.89 | 01/mar | 4.93 ± 3.85 | 4.18 | 2.05 - 7.53 | 4.09 ± 3.95 | 1.80 | 1 - 6 | 0.078 | |||
| Surgery timing | <0.001 | ||||||||||||
| Elective | 86.7 | 45.9 | 77.3 | ||||||||||
| Urgency | 13.3 | 45.9 | 22.7 | ||||||||||
| Emergency | 0.0 | 8.1 | 0.0 | ||||||||||
| Δ RT-PCR+ to | -48.4±51.6 | -35 | -70 | 4.74 ± 3.36 | 5.00 | 02/ago | 23.7 ± 17.3 | 16.0 | 12 - 28 | <0.001 | |||
BMI=body mass index; CAD=coronary artery disease; CKD=chronic kidney disease; COPD=chronic obstructive pulmonary disease; EuroSCORE II=European System for Cardiac Operative Risk Evaluation; HBP=high blood pressure; IQR=interquartile range; MI=myocardial infarction; RT-PCR=reverse transcriptase-polymerase chain reaction; SD=standard deviation
Generalized linear model with gamma distribution
General linear model with Gaussian distribution
Fisher's exact test
Clinical outcomes according to group allocation.
| Clinical outcomes | Total | Group 1 | Group 2 | Group 3 | |
|---|---|---|---|---|---|
| (n=104) | (n=45) | (n=37) | (n=22) | ||
| Vasoactive drugs use (%) | 81.9 | 75.6 | 86.8 | 86.4 | 0.369 |
| ICU length of stay (days) | 6 (4 - 11) | 5 (4 - 8) | 8 (4 -12) | 7.5 (5 - 15.5) | 0.310 |
| Total postoperative days | 11.5 (6 - 24) | 7 (5 - 14) | 12 (8 - 23) | 24 (20 - 41) | < 0.001 |
| Postoperative complications (%) | 52.4 | 33.3 | 68.4 | 63.6 | 0.003 |
| AKI | 25.0 | 11.4 | 36.8 | 31.8 | 0.016 |
| RRT | 9.5 | 2.2 | 13.2 | 18.2 | 0.044 |
| Cardiogenic shock | 23.1 | 15.9 | 26.3 | 31.8 | 0.294 |
| ARDS | 17.1 | 4.4 | 18.4 | 40.9 | < 0.001 |
| Pneumonia | 42.3 | 22.7 | 60.5 | 50.0 | 0.002 |
| Deaths | 25 | 2 | 17 | 6 | < 0.001 |
| Mortality rate | 24.0 | 4.4 | 45.9 | 27.3 | < 0.001 |
AKI=acute kidney injury; ARDS=acute respiratory distress syndrome; ICU=intensive care unit; RRT=renal replacement therapy Hospitalization days are presented in median (interquartile range).
Generalized linear model with gamma distribution with Bonferroni post hoc test
Fisher's exact test
P<0.001 compared to group 1
Postoperative complications and mortality in regard of group allocation.
| Postoperative complications | ||||||
|---|---|---|---|---|---|---|
|
|
|
|
|
| ||
| 2 | - | 1 | 4.45 | 1.64 - 12.87 | 2.86 | 0.013 |
| 3 | - | 1 | 3.44 | 1.20 - 10.42 | 2.26 | 0.071 |
|
| ||||||
|
|
|
|
|
| ||
| 2 | - | 1 | 14.85 | 3.55 - 102.92 | 3.65 | 0.003 |
| 3 | - | 1 | 7.77 | 1.59 - 57.14 | 2.41 | 0.018 |
AIC=Akaike's information criterion; CI=confidence interval
Adjusted by the type of surgery, i.e., elective, urgency, or emergency
AIC=140.90
AIC=99.19
| Abbreviations, acronyms & symbols | ||||
|---|---|---|---|---|
| AIC | = Akaike’s information criterion | HBP | = High blood pressure | |
| AKI | = Acute kidney injury | ICU | = Intensive care unit | |
| ARDS | = Acute respiratory distress syndrome | IQR | = Interquartile range | |
| BMI | = Body mass index | MI | = Myocardial infarction | |
| CAD | = Coronary artery disease | OR | = Odds ratio | |
| CI | = Confidence interval | RNA | = Ribonucleic acid | |
| CKD | = Chronic kidney disease | RRT | = Renal replacement therapy | |
| COPD | = Chronic obstructive pulmonary disease | RT-PCR | = Reverse transcriptase-polymerase chain reaction | |
| COVID-19 | = Coronavirus disease 2019 | SARS-CoV-2 | = Severe acute respiratory syndrome coronavirus | |
| EuroSCORE | = European System for Cardiac Operative Risk Evaluation | SD | = Standard deviation | |
| GzLM | = Generalized linear models | |||
| Authors' roles & responsibilities | |
|---|---|
| WJG | Substantial contributions to the participated in the design, data collection and interpretation, drafting, and revising of this manuscript; drafting the work or revising it critically for important intellectual content; agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved; final approval of the version to be published |
| IR | Substantial contributions to the design, data collection and interpretation, drafting, and revising of this manuscript; final approval of the version to be published |
| WSP | Substantial contributions to the design, data collection and interpretation, drafting, and revising of this manuscript; final approval of the version to be published |
| AHBP | Substantial contributions to the design, data collection and interpretation, drafting, and revising of this manuscript; final approval of the version to be published |
| PMSS | Substantial contributions to the design, data collection and interpretation, drafting, and revising of this manuscript; final approval of the version to be published |
| LAAC | Substantial contributions to the design, data collection and interpretation, drafting, and revising of this manuscript; final approval of the version to be published |
| MMPT | Substantial contributions to the design, data collection and interpretation, drafting, and revising of this manuscript; final approval of the version to be published |
| LPO | Substantial contributions to the design, data collection and interpretation, drafting, and revising of this manuscript; final approval of the version to be published |
| CB | Substantial contributions to the design, data collection and interpretation, drafting, and revising of this manuscript; final approval of the version to be published |
| IB | Substantial contributions to the design, data collection and interpretation, drafting, and revising of this manuscript; final approval of the version to be published |
| RSLM | Substantial contributions to the design, data collection and interpretation, drafting, and revising of this manuscript; final approval of the version to be published |
| NAHJ | Substantial contributions to the design, data collection and interpretation, drafting, and revising of this manuscript; final approval of the version to be published |
| GFV | Substantial contributions to the design, data collection and interpretation, drafting, and revising of this manuscript; final approval of the version to be published |
| JNRB | Substantial contributions to the design, data collection and interpretation, drafting, and revising of this manuscript; final approval of the version to be published |
| CAT | Substantial contributions to the design, data collection and interpretation, drafting, and revising of this manuscript; final approval of the version to be published EASM Substantial contributions to the design, data collection and interpretation, drafting, and revising of this manuscript; final approval of the version to be published |
| CS | Substantial contributions to the design, data collection and interpretation, drafting, and revising of this manuscript; final approval of the version to be published |
| AR | Substantial contributions to the design, data collection and interpretation, drafting, and revising of this manuscript; final approval of the version to be published |
| LMN | Substantial contributions to the design, data collection and interpretation, drafting, and revising of this manuscript; final approval of the version to be published |
| ARR | Substantial contributions to the design, data collection and interpretation, drafting, and revising of this manuscript; final approval of the version to be published |
| FKM | Substantial contributions to the design, data collection and interpretation, drafting, and revising of this manuscript; final approval of the version to be published |
| IEC | Substantial contributions to the design, data collection and interpretation, drafting, and revising of this manuscript; final approval of the version to be published |
| RCS | Substantial contributions to the design, data collection and interpretation, drafting, and revising of this manuscript; final approval of the version to be published |
| DLRVP | Substantial contributions to the design, data collection and interpretation, drafting, and revising of this manuscript; final approval of the version to be published |
| ACMJ | Substantial contributions to the design, data collection and interpretation, drafting, and revising of this manuscript; final approval of the version to be published |
| DSV | Substantial contributions to the design, data collection and interpretation, drafting, and revising of this manuscript; final approval of the version to be published |
| JHSAC | Substantial contributions to the design, data collection and interpretation, drafting, and revising of this manuscript; final approval of the version to be published |
| JCJ | Substantial contributions to the design, data collection and interpretation, drafting, and revising of this manuscript; final approval of the version to be published |
| HMRC | Substantial contributions to the design, data collection and interpretation, drafting, and revising of this manuscript; final approval of the version to be published |
| GK | Substantial contributions to the design, data collection and interpretation, drafting, and revising of this manuscript; final approval of the version to be published |
| ZSAMA | Substantial contributions to the design, data collection and interpretation, drafting, and revising of this manuscript; final approval of the version to be published |
| GRF | Substantial contributions to the design, data collection and interpretation, drafting, and revising of this manuscript; final approval of the version to be published |
| PRLL | Substantial contributions to the design, data collection and interpretation, drafting, and revising of this manuscript; final approval of the version to be published |
| ACF | Substantial contributions to the design, data collection and interpretation, drafting, and revising of this manuscript; final approval of the version to be published |
| DCB | Substantial contributions to the design, data collection and interpretation, drafting, and revising of this manuscript; final approval of the version to be published |
| FRHDLC | Substantial contributions to the design, data collection and interpretation, drafting, and revising of this manuscript; final approval of the version to be published |
| UAC | Substantial contributions to the design, data collection and interpretation, drafting, and revising of this manuscript; final approval of the version to be published |
| BCB | Substantial contributions to the design, data collection and interpretation, drafting, and revising of this manuscript; final approval of the version to be published |
| CHDM | Substantial contributions to the design, data collection and interpretation, drafting, and revising of this manuscript; final approval of the version to be published |
| LG | Substantial contributions to the design, data collection and interpretation, drafting, and revising of this manuscript; final approval of the version to be published |
| KBSP | Substantial contributions to the design, data collection and interpretation, drafting, and revising of this manuscript; final approval of the version to be published |
| FGJ | Substantial contributions to the design, data collection and interpretation, drafting, and revising of this manuscript; final approval of the version to be published |
| FRAO | Substantial contributions to the design, data collection and interpretation, drafting, and revising of this manuscript; final approval of the version to be published |
| RBS | Substantial contributions to the design, data collection and interpretation, drafting, and revising of this manuscript; final approval of the version to be published |
| ACZ | Substantial contributions to the design, data collection and interpretation, drafting, and revising of this manuscript; final approval of the version to be published |
| RGSM | Substantial contributions to the design, data collection and interpretation, drafting, and revising of this manuscript; final approval of the version to be published |
| LCBJ | Substantial contributions to the design, data collection and interpretation, drafting, and revising of this manuscript; final approval of the version to be published |
| RT | Substantial contributions to the design, data collection and interpretation, drafting, and revising of this manuscript; final approval of the version to be published |
| ABJ | Substantial contributions to the design, data collection and interpretation, drafting, and revising of this manuscript; final approval of the version to be published |
| LVF | Substantial contributions to the design, data collection and interpretation, drafting, and revising of this manuscript; final approval of the version to be published |
| PF | Substantial contributions to the design, data collection and interpretation, drafting, and revising of this manuscript; final approval of the version to be published |
| FO | Substantial contributions to the design, data collection and interpretation, drafting, and revising of this manuscript; final approval of the version to be published |
| RMJ | Substantial contributions to the design, data collection and interpretation, drafting, and revising of this manuscript; final approval of the version to be published |
| TCVNA | Substantial contributions to the design, data collection and interpretation, drafting, and revising of this manuscript; final approval of the version to be published |
| OPB | Substantial contributions to the design, data collection and interpretation, drafting, and revising of this manuscript; final approval of the version to be published |
| ACPS | Substantial contributions to the design, data collection and interpretation, drafting, and revising of this manuscript; final approval of the version to be published |
| RTBT | Substantial contributions to the design, data collection and interpretation, drafting, and revising of this manuscript; final approval of the version to be published |
| ILLC | Substantial contributions to the design, data collection and interpretation, drafting, and revising of this manuscript; final approval of the version to be published |
| ENG | Substantial contributions to the design, data collection and interpretation, drafting, and revising of this manuscript; final approval of the version to be published |
| PHR | Substantial contributions to the design, data collection and interpretation, drafting, and revising of this manuscript; final approval of the version to be published |
| LPG | Substantial contributions to the design, data collection and interpretation, drafting, and revising of this manuscript; final approval of the version to be published |
| NHGS | Substantial contributions to the design, data collection and interpretation, drafting, and revising of this manuscript; final approval of the version to be published |
| RL | Substantial contributions to the design, data collection and interpretation, drafting, and revising of this manuscript; final approval of the version to be published |
| SG | Substantial contributions to the participated in the design, data collection and interpretation, drafting, and revising of this manuscript; drafting the work or revising it critically for important intellectual content; agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved; final approval of the version to be published |